Author:
Chen Shaohua,Zha Xianfeng,Shi Li,Zhou Lingling,Yang Lijian,Li Bo,Wu Xiuli,Zhong Jun,Zhang Tao,Lu Yuhong,Zhu Kanger,Li Yangqiu
Funder
National Natural Science Foundation of China
the China Postdoctoral Science Foundation
the Guangdong Natural Science Foundation
the Foundation for High-level Talents in Higher Education of Guangdong, China
the Medical Science Foundation of Guangdong Province
the Guangzhou Science and Technology Project foundation
the Fundamental Research Funds for the Central Universities
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Biology,Hematology
Reference12 articles.
1. Löwenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract Res ClinHaematol. 2001;14:65–75.
2. Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, et al. Azacitidine in patients with WHO-defined AML—results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J HematolOncol. 2013;6:32.
3. van der Helm LH, Scheepers ER, Veeger NJ, Daenen SM, Mulder AB, van den Berg E, et al. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol. 2013;6:29.
4. Shi L, Chen S, Zha X, Xu Y, Xu L, Yang L, et al. Enhancement of the TCRζ expression, polyclonal expansion and activation of T cells from patients with AML after IL-2, IL-7 and IL-12 induction. DNA Cell Biol. 2015 Mar 10. [Epub ahead of print]
5. Li Y. Alterations in the expression pattern of TCR zeta chain in T cells from patients with hematological diseases. Hematology. 2008;13:267–75.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献